Second-generation antipsychotic agents (SGAs) are increasingly replacing first-generation antipsychotic agents due to their superior activity against the negative symptoms of schizophrenia, decreased extrapyramidal symptoms and better tolerability. However, some SGAs are associated with adverse metabolic effects as significant weight gain, lipid disorders and diabetes mellitus. The pathogenesis of SGA-induced disturbances of glucose homeostasis is unclear. In vivo studies suggest a direct influence of SGAs on peripheral insulin resistance. To this end, we analyzed whether olanzapine might alter glycogen synthesis and the insulin-signaling cascade in L6 myotubes. Glycogen content was diminished in a doseand time-dependent manner. Within the insulin-signaling cascade IRS-1 tyrosine phosphorylation was induced several fold by insulin and was diminished by preincubation with olanzapine. IRS-1-associated PI3K activity was stimulated by insulin three-fold in L6 myotubes. Olanzapine inhibited insulin-stimulated IRS-1-associated PI3K activity in a dosedependent manner. Protein mass of AKT, GSK-3 and GS was unaltered, whereas phosphorylation of AKT and GSK-3 was diminished, and pGS was increased. Finally, we compared olanzapine with amisulpride, an SGA clinically not associated with the induction of diabetes mellitus. Glycogen content was diminished in olanzapine-preincubated L6 cells, whereas this effect was not observed under the amisulpride conditions. We conclude that olanzapine impairs glycogen synthesis via inhibition of the classical insulin-signaling cascade and that this inhibitory effect may lead to the induction of insulin resistance in olanzapine-treated patients.
Antipsychotic medications are a mainstay in the treatment of schizophrenia and are widely used in other psychiatric conditions. Second-generation antipsychotic agents (SGAs) are increasingly replacing first-generation antipsychotic agents (FGAs), mainly due to a decreased risk for extrapyramidal symptoms, better overall tolerability, as well as efficacy advantages in some areas. 1, 2 However, some of these SGAs are associated with adverse metabolic effects such as substantial weight gain, the induction of insulin resistance and lipid disorders. Among these, clozapine and olanzapine induce the most significant weight gain. In one prospective trial in olanzapine-treated patients this weight gain was mainly due to an increase in body fat. 3 Both of these antipsychotics have been associated with disturbances in glucose metabolism (for a review see Consensus development conference on antipsychotic drugs and obesity and diabetes 4 ). The pathogenesis of olanzapine-and clozapineinduced disturbances of glucose homeostasis is unclear. It has recently been demonstrated that clozapine and olanzapine, in contrast to FGAs, increase basal insulin release in vitro. 5, 6 However, in vivo, neither olanzapine nor risperidone altered beta cell function in healthy volunteers studied in hyperglycemic clamp experiments. 7 In a prospective study of schizophrenia patients and a control group we confirmed and extended these results. In these subjects beta cell function remained unaltered, whereas the index representing peripheral insulin resistance increased significantly. 8 Diabetes mellitus induced by treatment with some SGAs occurred in many cases within days to weeks after initiation of SGA therapy, in some cases hyperglycemia promptly resolved after discontinuation of the medication and several reports have documented recurrent hyperglycemia after a rechallenge with the same drug. 4 One possible pathomechanism for hyperglycemia induced by these SGAs is the reported weight gain and/or a change in body fat distribution with a shift to a predominant visceral fat type. Alternatively, SGAinduced diabetes may occur through a direct effect on insulin-sensitive target tissues by impairment of the insulin action, that is, induction of insulin resistance, via humoral and/or cellular pathways. 9, 10 However, humoral insulin resistance factors such as FFAs, TNF-a, adiponectin, and resistin remained stable over an observation period of 8 weeks when compared with the patients baseline values and when analyzing between-group change scores comparing patients and control subjects.
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To further explore the pathomechanism of SGAinduced diabetes we performed experiments to evaluate whether olanzapine has a direct effect on insulin-sensitive target tissues. As a cell culture model of skeletal muscle, the main insulin-sensitive target tissue, we analyzed glycogen synthesis and several steps of the insulin-signaling cascade in L6 myotubes.
Materials and methods

Materials
The L6 rat skeletal muscle cell line was obtained from ATCC. a-MEM, amyloglucosidase and the L-a-PI3-standard were purchased from Sigma, FCS from PromoCell and fatty acid-/insulin-free BSA from Valeant Pharmaceuticals. ECL was purchased from Amersham Biosciences, ( 32 P)-ATP from Perkin Elmer, phosphatidylinositol from Avanti Polar Lipids and the 4-15% linear-gradient mini gels from Biorad. Anti-IRS-1 antibody and anti-GSK-3 antibodies were obtained from Upstate; anti-phospho-GSK-3a/bser21/9, anti-phospho-AkT-ser473 and anti-AkT antibodies were from Cell Signaling Technology. Olanzapine was kindly obtained from Eli Lilly, Indianapolis, USA, and amisulpride from Sanofi-Synthelabo, Chilly-Mazarin, France, respectively.
Cell culture
Stock cells of the L6 rat skeletal muscle cell line were stored frozen in liquid nitrogen and a fresh vial of cells was thawed for every experiment. Cells were cultured in a-MEM containing 10% FCS to confluence and then switched to the same media containing 2% FCS. Cells, cultured in 60 mm culture dishes were used up to the fifth passage, and experiments were performed with fully differentiated myotubes 12-14 days post confluence.
Incubation experiments
At 1 day prior to the experiments, the media was replaced by serum-free a-MEM containing 0.25% fatty acid-and insulin-free BSA, and cells were incubated in the absence or presence of the respective concentrations of olanzapine. Cells were incubated with or without insulin for various lengths of time, lysed and analyzed for glycogen content and insulin signaling as detailed below. To test whether olanzapine and amisulpride have toxic effects on L6 cells, we measured lactate dehydrogenase (LDH) in the incubation media at the beginning and at the end of the incubations. In parallel, we examined LDH values under control conditions. Experiments with a significant rise in the LDH concentrations above that seen in the control conditions were excluded from further procedure and analyses.
IRS-1-associated PI3K activity For this purpose, cells were stimulated with 100 nM insulin for 10 min, washed three times with buffer 1 (20 nM Tris-HCl, pH 7.4, 137 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 and 1 mM Na 3 VO 4 ) and then lysed in buffer 1 containing 1% NP-40, 1 mM PMSF, 2 mg/ml leupeptin, 20 mM sodium pyrophosphate and 50 mM NaF. After centrifugation at 14 000 g for 10 min at 41C, the supernatant was immunoprecipitated using an anti-IRS-1 antibody for 2 h at 41C. Immunoprecipitates were washed three times with buffer 1 containing 1% NP-40, 1 mM PMSF, 2 mg/ml leupeptin, 20 mM sodium pyrophosphate and 50 mM NaF and then washed for five times with buffer 2 (25 mM MOPS, pH 7.3, 5 mM MgCl 2 , 1 mM EGTA, 1 mM Na 3 VO 4 , 1 mM PMSF, 2 mg/ml leupeptin, 20 mM sodium pyrophosphate and 50 mM NaF). The immunoprecipitate was then resuspended in 50 ml buffer 2 and heated to 371C in a heating block. To start the reaction, 10 ml of 0.4 mg/ ml sonicated phosphatidylinositol and 20 ml of ATP mix (buffer 2 containing 60 mM ATP and 25 mCi ( 32 P)-ATP) were added. After 10 min at 371C, the reaction was stopped by the addition of 37% HCl/methanol (1 : 1, v/v). Lipids were extracted with chloroform and the organic phase was removed and applied to silica gel TLC plates. The plates were developed in chloroform/methanol/water/ammonia (60/47/11.3/2, v/v) and the PI3-product was identified by its comigration with a L-a-PI3-standard and quantified on a Packard Cyclone phosphoimager. 12 Western blot analysis After stimulation of cells with 100 nM insulin for 5 min, cells were washed with PBS and solubilized in lysis buffer (50 mM HEPES, pH 7.5, 1% Triton X-100, 150 mM NaCl, 10 mM EDTA, 10% glycerol, 10 mg/ml trypsin inhibitor, 1 mM Na 3 VO 4 , 1 mM PMSF, 5 mg/ml pepstatin A, 10 mg/ml aprotinin, 10 mg/ml leupeptin, 10 mM NaF and 10 nM sodium pyrophosphate). After incubation on ice for 30 min, samples were centrifuged at 10 000 g for 5 min at 41C and the protein content of the supernatant was determined according to the method of Bradford. An aliquot was taken for direct blotting, and the remaining supernatant was used for immunoprecipitation with an anti-IRS-1 antibody overnight at 41C. The immune complexes were collected on protein A-agarose during 2-h incubation at 41C. The beads were washed four times with lysis buffer including 0.1% instead of 1% Triton X-100 and boiled for 5 min in Laemmli buffer. For direct blotting, Laemmli buffer was added to the aliquot of the detergent extract. The solubilized proteins were resolved by SDS-PAGE on 4-15% linear-gradient mini gels and subjected to immunoblotting using respective antibodies. For these experiments, the same blot was stripped several times with stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, 62.5 mM Tris/HCl, pH 6.7) at 701C for 30 min and reprobed with respective antibodies. Upon incubation with secondary antibodies, immunoreactive bands were detected by enhanced chemiluminescence according to the manufacturer's instructions.
Glycogen content
After incubation of cells with (100 nM) or without insulin for 3 h at 371C, we determined glycogen content by a modification of the method described by Keppler and Decker. Briefly, after washing four times with ice-cold PBS, cells were collected in 0.6 N HClO 4 and homogenized by sonification in ice water. Aliquots of the homogenate were incubated with 1 M KHCO 3 and 10 mg/ml amyloglucosidase in 0.2 M acetate buffer (pH 4.8) for 2 h at 401C. The reaction was stopped by addition of chilled 2 N HClO 4 and centrifugation at 14 000 g at 41C for 10 min. Glucose concentration was determined using a Cobas MIRA analyzer from Roche.
Statistical analysis
Statistical significance was accepted at Po0.05. P-values were tested using one way ANOVA (LSD), the Kruskal-Wallis test or the t-test. All values were expressed as means7SEM.
Results
To test whether skeletal muscle cells represent a 'peripheral' target tissue in the pathogenesis of SGAinduced dysregulation of the glucose homeostasis we analyzed glycogen synthesis and several steps of the insulin-signaling cascade of nonoxidative glucose metabolism in L6 myotubes.
Glycogen synthesis First, we tested whether olanzapine affects the glycogen synthesis in L6 myotubes. 13 Cells were incubated in the absence or presence of 1, 10 and 100 mM of olanzapine for various time periods and subsequently incubated without or with insulin for 3 h and analyzed for glycogen content. Olanzapine inhibited glycogen synthesis in a time-and dosedependent manner both in the absence or presence of insulin. This inhibition reached a level of statistical significance at an olanzapine concentration of 100 mM after 24 h under the basal condition and after 12 h at an olanzapine concentration of 100 mM in the insulinstimulated state (Figure 1 ). These experiments demonstrated the time-and dose dependence of the inhibitory effect of olanzapine on glycogen synthesis and also served as dose-and time-finding study for the subsequent experiments on the insulin-signaling cascade.
Olanzapine and the insulin-signaling cascade Within the insulin-signaling cascade, IRS-1 tyrosine phosphorylation was induced several fold by insulin and was diminished by preincubation with olanzapine ( Figure 2 ). Next, we examined IRS-1-associated PI-3k activity, which is essential for insulin-induced translocation of GLUT-4 and glucose transport. 14, 15 IRS-1-associated PI-3k activity was stimulated threefold by insulin. Preincubation for 72 h with 10 mM of olanzapine reduced insulin-stimulated PI3K activity by one-third when compared to the condition minus olanzapine plus insulin. Preincubation with 100 mM of olanzapine blocked insulin-stimulated PI3k activity to basal levels (Po0.05 when compared to the minus olanzapine plus insulin condition). Preincubation of the L6 cells with Wortmannin served as a negative control (Figure 3) . The main downstream targets of PI-3k are phosphoinositide-dependent kinase 1 (PDK1) and the serine-threonine kinase AKT. Phosphorylation stimulates the catalytic activity of AKT, which results in the phosphorylation of a number of other proteins regulating cell growth, cell survival, and cell cycle entry. 16 To test whether olanzapine also affects AKT, Western blotting of lysates of L6 myotubes was performed with antibodies recognizing AKT and AKT phosphorylated at amino-acid residue Thr 308, 17 respectively (Figure 4 ). Statistical analysis of the Western blots revealed no differences in the protein mass as detected with the AKT antibody. Phosphorylated AKT was stimulated significantly by incubation with 100 nM insulin. The 10 and 100 mM olanzapine concentrations diminished the insulin-stimulated AKT phosphorylation in a dosedependent manner that was statistically significant between the minus olanzapine vs 100 mM olanzapine conditions.
The downstream signaling target of AKT that regulates synthesis of glycogen is glycogen synthase Olanzapine inhibits IRS-1 tyrosine phosphorylation. L6 myotubes were incubated in the absence or in the presence of 10 and 100 mM olanzapine for 72 h. Cells were subsequently incubated without or with 100 nM insulin for 5 min and solubilized in lysis buffer. IRS-1 was immunoprecipitated and the immune complexes were collected on protein A-agarose. Samples were subjected to SDS-PAGE and Western blotting was performed with antibodies recognizing IRS-1 and pY, respectively. Statistical analysis of the Western blots revealed no differences in the protein mass as detected with the IRS-1 antibody. PY was stimulated significantly by incubation with 100 nM insulin. The 10 and 100 mM olanzapine diminished the insulinstimulated IRS-1 phosphorylation when compared to the minus olanzapine condition. Figure 3 Olanzapine inhibits the IRS-11-associated PI3K activity. Cells were incubated in the presence or absence of 10 and 100 mM of olanzapine for 72 h. Subsequently L6 myotubes were stimulated with 100 nM insulin or without insulin for 10 min and solubilized in lysis buffer. IRS-1 was immunoprecipitated with a polyclonal antibody and IRS-1-associated PI3K activity was determined as described in the Materials and methods section. Experiments were performed 2-9 times in duplicate. Statistical analysis revealed a significant stimulation PI3K activity upon incubation with insulin. Preincubation with olanzapine diminished insulinstimulated PI3K activity in a dose-dependent manner that was statistically significant upon preincubation with 100 mM olanzapine. Preincubation of the L6 cells with Wortmannin served as a negative control. Olanzapine inhibits AkT phosphorylation. L6 myotubes were incubated in the absence or in the presence of 10 and 100 mM olanzapine for 72 h. Cells were subsequently incubated without or with 100 nM insulin for 5 min and solubilized in lysis buffer. Lysates were subjected to SDS-PAGE and Western blotting was performed with an antibody recognizing AkT and phospho-AkT (Thr 308), respectively. Statistical analysis of the Western blots revealed no differences in the protein mass as detected with the AkT antibody. Phospho-akt was stimulated significantly by incubation with 100 nM insulin. The 10 and 100 mM olanzapine diminished the insulin-stimulated AkT phosphorylation in a dose-dependent manner that was statistically significant between theÀolanzapine vs 100 mM olanzapine conditions, respectively, when analyzing six experiments performed in duplicate.
kinase 3 (GSK-3). 18 GSK-3 is constitutively active in unstimulated cells and phosphorylates many proteins including glycogen synthase (GS) to keep these proteins in an inactive state. 19, 20 Thus, Western blotting with antibodies recognizing GSK-3a and b as well as phospho-GSK-3a and b was performed ( Figure 5 ). Statistical analysis of these Western blots revealed no differences in the protein mass of the 46 and 51 kDa isoforms detected with the GSK-3a/b antibody. Phosphorylation of GSK-3a/b was stimulated by incubation with 100 nM insulin and preincubation with 100 mM olanzapine diminished insulin-stimulated GSK-3a/b phosphorylation significantly.
As GS is the next protein in the cascade leading to glycogen synthesis we performed Western blots to examine its regulation. 21 Since phosphorylated GSK-3 was diminished in the experiments described above, we expected phosphorylation of GS to increase. In fact, phosphorylation of GS at Ser641 22 was increased by incubation with 100 mM of olanzapine in Western blotting experiments performed with an antibody recognizing p-GS ( Figure 6 ).
Effect of olanzapine vs amisulpride on glycogen content
Finally, we compared olanzapine with amisulpride, an SGA clinically not associated with the induction of diabetes mellitus. 4 Glycogen content was diminished in olanzapine preincubated L6 cells to 40% of the control in the minus insulin experiments and to 80% in the plus insulin condition, whereas amisulpride did not inhibit the glycogen content in L6 cells (95 vs 100% in the minus insulin condition, 178 vs 178% in the insulin-stimulated condition) (Figure 7 ).
Discussion
Numerous reports have documented the onset and/or exacerbation of diabetes, in some cases with devel- Figure 5 Olanzapine inhibits GSK-3 phosphorylation. L6 myotubes were incubated in the absence or in the presence of 0.1, 1.0, 10 and 100 mM olanzapine for 72 h. Cells were subsequently incubated without or with 100 nM insulin for 5 min and solubilized in lysis buffer. Lysates were subjected to SDS-PAGE and Western blotting was performed with an antibody recognizing GSK-3a and b and phospho-GSK-3a and b, respectively. Statistical analysis of the Western blots revealed no differences in the protein mass of the 46 and 51 kDa isoforms as detected with the GSK-3a/b antibody. Phospho-GSK-3a/b was stimulated significantly by incubation with 100 nM insulin. Olanzapine diminished the insulin-stimulated GSK-3a/b phosphorylation at highest concentration of olanzapine. Experiments were performed four times.
Direct blot: pGS
Ola in µM 0 0 100 100 10 0 0 100 100 10 Figure 6 Olanzapine inhibits GS dephosphorylation. L6 myotubes were incubated in the absence or in the presence of 10 and 100 mM olanzapine for 72 h. Cells were subsequently incubated without or with 100 nM insulin for 5 min and solubilized in lysis buffer. Lysates were subjected to SDS-PAGE and Western blotting was performed with an antibody recognizing phospho-GS. Olanzapine (100 mM) stimulated the phosphorylation of GS both without and with 100 nM insulin. Experiments were performed four times. Figure 7 Effect of amisulpride vs olanzapine on glycogen synthesis. L6 myotubes were incubated in the absence or in the presence of 50 mM of olanzapine or amisulpride for 72 h. Cells were subsequently incubated in absence or presence of olanzapine or amisulpride without or with insulin for 3 h and analyzed for glycogen content. Olanzapine inhibited glycogen synthesis both without and with insulin stimulation, whereas amilsulpride had no effect on glycogen synthesis when compared to the control condition. Olanzapine inhibited glycogen content both in the insulin minus and insulin-stimulated conditions statistically significant, whereas amisulpride had no effect on glycogen content when compared to the control experiments. Experiments were performed at least five times in duplicate.
opment of hyperglycemic crisis or diabetic ketoacidosis, following the initiation of therapy with some of the SGAs. [23] [24] [25] [26] [27] These studies consistently proofed a higher risk of developing diabetes in patients treated with olanzapine and clozapine. 4 In a prospective controlled study we found that treatment with olanzapine leads to weight gain, which is mainly due to an increase in fat mass. 3 As a model of the glucose-insulin feedback system in the overnight-fasted state we calculated the homeostasis model assessment (HOMA) index for both beta cell function and insulin resistance. The HOMA index for beta cell function remained stable throughout the study period. In contrast, the HOMA index for insulin resistance increased significantly from an average of 1.31-2.59 mmol mU À1 l À2 in the olanzapine-treated patients, suggesting the induction of insulin resistance in these patients. 8 A recent study by Henderson et al 28 confirmed and extended these results. In this study, both nonobese clozapine-and olanzapinetreated groups displayed significant insulin resistance and an impairment of glucose effectiveness when compared with risperidone-treated subjects.
This insulin resistance could be due to alterations in insulin sensitivity in either peripheral or/and hepatic tissues via humoral and/or cellular pathways. Several insulin resistance-inducing factors have been identified in the past. FFAs derived from adipocytes are constantly elevated in insulin-resistant subjects. FFAs inhibit glucose uptake, glycogen synthesis and glucose oxidation, and increase hepatic glucose output. 29 On a cellular level, elevated FFAs inhibit insulin-stimulated IRS-1 tyrosine phosphorylation and also IRS-1-associated PI3K, and in contrast, increase insulin-stimulated IRS-1 serine phosphorylation, specifically at residue 307. 30, 31 Adipose tissue also secretes a plethora of adipocytokines, with some of them inducing insulin-resistance states, and in particular TNF-a, which is increased in human obesity and induces insulin resistance via increasing serine phosphorylation of IRS-1. 32 Interestingly, both TNF-a and FFAs increase insulin-stimulated IRS-1 serine phosphorylation at residue 307, which suggests a common pathway of insulin resistance-inducing mechanism of these two compounds. 30, 33 Additional candidates of insulin resistance-inducing or protective factors are leptin, adiponectin and resistin, although the molecular pathways involved in the action of these adipocytokines is currently not well understood. 9, 10, 34 However, some of the humoral insulin resistance-inducing factors (FFAs, TNF-a, adiponectin and resistin) remained stable in a prospective study comparing olanzapine-treated patients and control subjects.
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To test the hypothesis that cellular pathways are central in olanzapine-induced insulin resistance we examined whether olanzapine alters glycogen synthesis and some steps of the insulin-signaling cascade in L6 cells. IRS-1 tyrosine phosphorylation was reduced under the 10 and 100 mM olanzapine concentrations. At 10 and 100 mM concentrations, olanzapine inhibited insulin-stimulated IRS-1-associated PI3K activity by 28 and 66%, respectively. Phosphorylation of AKT and GSK-3 was diminished, and pGS was increased. Consistently, olanzapine diminished glycogen content in L6 myotubes in a dose-and timedependent manner. Finally, we compared olanzapine with amisulpride, an SGA clinically not associated with the induction of diabetes mellitus. Glycogen content was diminished in olanzapine preincubated L6 cells, whereas this effect was not observed under the amisulpride conditions. Thus, the olanzapine-induced disturbance in glucose homeostasis may be due to the induction of insulin resistance in the peripheral skeletal muscle tissue by inhibiting glycogen synthesis mediated by inhibition of the classical insulin signaling and is specific for olanzapine.
Therapeutic serum levels of olanzapine are in the range of 0.1-0.3 mM. 35 On the other hand, it is well documented, that antipsychotic drugs accumulate in the brain and in fat tissue to levels that are 25-30 times higher than the therapeutic serum levels. 36 In addition, the presence of active metabolites may further increase the effective concentration of a drug. Thus, the therapeutic plasma levels of the respective drugs are likely considerably lower than tissue concentrations.
We used concentrations similar to those in the studies by Dwyer et al. In one of their papers they investigated the effect of olanzapine on L6 cells myotubes, the cell line used in this study. 37 They found that olanzapine in concentrations higher than 100 mM and for 72 h was 'slightly' toxic in the MTS assay, an assay that is highly sensitive to determine viability of cells.
Melkersson et al 5, 6 have used olanzapine at a concentration of 1 mM throughout their studies, but they cultured human pancreas cells for their experiments. Other groups that have studied the inhibition of the insulin release by antipsychotics used concentrations of the respective antipsychotics ranging from 1 to 100 mM. 5, [38] [39] [40] [41] There are some restrictions in translating results obtained in the cell culture system of L6 myotubes to the human system. First, this cell line is derived from the rat, thus species-specific differences must be considered. Second, these myotubes are stimulated by an unusual high concentration of human insulin, that is 100-fold above the postprandial insulin levels found in human subjects. Third, several other groups used this cell line in their studies and some of them used up to 1000-fold higher concentrations of the biological substances that were studies. For instance, TNF-a was used at a concentration of 2-10 ng/ml, a value 1000-fold above the levels found in human plasma. [42] [43] [44] [45] Similar experimental conditions have been described for the insulin resistance-inducing factors IL-1 and IL-6.
A recent consensus development conference on antipsychotic drugs and obesity and diabetes called for 'studies to determine whether the disorders of body weight and glucose and lipid metabolism are due to central nervous system or peripheral tissue actions of SGAs. 4 This report is in line with this recommendation. We conclude from our L6 myotube cell line experiments that glycogen synthesis and-in parallel-the insulin-signaling cascade is consistently impaired at various levels by olanzapine, and, thus, that olanzapine-induced insulin resistance might be due to an effect of this drug on peripheral muscle tissue action.
